DEERFIELD, Ill. & OSAKA & TOKYO, Japan--(BUSINESS WIRE)--Baxter International Inc. (Headquarters: Illinois, U.S.A.) (“Baxter”) and Takeda Pharmaceutical Company Limited (Headquarters: Osaka, Japan) (“Takeda”) today announced that the parties have completed a Development, License and Technology Transfer Agreement. Under the terms of the agreement, Takeda and Baxter will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market. Specifically:
